Lantheus Holdings LNTH
NASDAQ LNTH
$100.28 -0.20 (-0.20%)
As of: Aug 20, 2026 · 3:59 PM EDT

Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026)

Lantheus Holdings (LNTH) posted quarterly Net Income towards Common Stockholders of $118.4 million for Q1 2026, up 62.34% year-over-year from $72.9 million in Q1 2025, and up 118.93% quarter-over-quarter from $54.1 million in Q4 2025.

Lantheus Holdings (LNTH) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has reported Net Income towards Common Stockholders for 13 consecutive years, with $118.4 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders rose 62.34% year-over-year to $118.4 million; the TTM figure through Mar 2026 stood at $279.0 million (up 9.72% YoY), while the FY2025 annual figure was $233.6 million, down 25.25% from the prior year.
  • Net Income towards Common Stockholders improved to $118.4 million in Q1 2026 per LNTH's latest filing, from $54.1 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $132.0 million in Q3 2023 and bottomed at -$119.2 million in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged $59.8 million across 5 years, with a median of $62.1 million in 2024.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 196.37% — and 2024, when it jumped 4769.26%.
  • Lantheus Holdings' Net Income towards Common Stockholders stood at -$119.2 million in 2022, then soared by 185.05% to $101.4 million in 2023, then sank by 111.63% to -$11.8 million in 2024, then jumped by 558.76% to $54.1 million in 2025, then jumped by 118.93% to $118.4 million in 2026.
  • Business Quant data shows LNTH's Net Income towards Common Stockholders at $118.4 million in Q1 2026, $54.1 million in Q4 2025, and $27.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Lantheus Holdings 6.54 Bn 5.94 Bn 241.86 Mn 75.03 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 75.03 Mn
Mar 31, 2026 118.42 Mn
Dec 31, 2025 54.09 Mn
Sep 30, 2025 27.77 Mn
Jun 30, 2025 78.76 Mn
Mar 31, 2025 72.95 Mn
Dec 31, 2024 -11.79 Mn
Sep 30, 2024 131.09 Mn
Jun 30, 2024 62.07 Mn
Mar 31, 2024 131.07 Mn
Dec 31, 2023 101.36 Mn
Sep 30, 2023 131.96 Mn
Jun 30, 2023 94.13 Mn
Mar 31, 2023 -2.81 Mn
Dec 31, 2022 -119.19 Mn
Sep 30, 2022 61.23 Mn
Jun 30, 2022 43.06 Mn
Mar 31, 2022 42.96 Mn
Dec 31, 2021 -40.22 Mn
Sep 30, 2021 -13.42 Mn